2015
DOI: 10.3109/10715762.2015.1019347
|View full text |Cite
|
Sign up to set email alerts
|

Thiocyanate supplementation decreases atherosclerotic plaque in mice expressing human myeloperoxidase

Abstract: Elevated levels of the heme enzyme myeloperoxidase (MPO) are associated with adverse cardiovascular outcomes. MPO predominantly catalyzes formation of the oxidants hypochlorous acid (HOCl) from Cl−, and hypothiocyanous acid (HOSCN) from SCN−, with these anions acting as competitive substrates. HOSCN is a less powerful and more specific oxidant than HOCl, and selectively targets thiols; such damage is largely reversible, unlike much HOCl-induced damage. We hypothesized that increased plasma SCN−, and hence HOSC… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

2
37
0

Year Published

2015
2015
2024
2024

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 36 publications
(39 citation statements)
references
References 43 publications
2
37
0
Order By: Relevance
“…This may arise from upregulation of TrxR within the lung tissue, which can detoxify HOSCN, and hence preserve GSH (42). Similarly, supplementing atherosclerosis-prone mice, which overexpress human MPO, with SCNresulted in a marked decrease in plaque area (164). These protective effects have been detected at SCNlevels that can be readily achieved and tolerated in humans (164), but more work is needed to assess the mechanism(s) involved, and particularly whether this arises from an alteration in HOCl levels in these animals.…”
Section: Limiting Mpo Substrate Availabilitymentioning
confidence: 99%
“…This may arise from upregulation of TrxR within the lung tissue, which can detoxify HOSCN, and hence preserve GSH (42). Similarly, supplementing atherosclerosis-prone mice, which overexpress human MPO, with SCNresulted in a marked decrease in plaque area (164). These protective effects have been detected at SCNlevels that can be readily achieved and tolerated in humans (164), but more work is needed to assess the mechanism(s) involved, and particularly whether this arises from an alteration in HOCl levels in these animals.…”
Section: Limiting Mpo Substrate Availabilitymentioning
confidence: 99%
“…SCN − dose-dependently decreased cholesterol deposition in the aorta and kidneys of thyroidectomized rabbits given 0, 20 or 60 mg kg −1 potassium SCN − and 300 mg kg −1 cholesterol daily [56]. Giving 10 mM sodium SCN − in drinking water to LDL receptor-knockout, MPO-463G transgenic mice (an established proatherogenic model [168]) increased plasma SCN − >2-fold over baseline and decreased aortic arch plaque area by 26% compared to control [16]. Together these studies suggest SCN − may protect against adverse cardiovascular outcomes, in agreement with recent clinical research [18].…”
Section: Clinical and In Vivo Research On The Health Effects Of Scn−mentioning
confidence: 99%
“…The role of SCN − in airway host defense was underscored by observations of deficient or dysregulated SCN − efflux in the epithelial secretions of CF cells which impaired the cells’ ability to kill bacteria [12,13]. Recent and ongoing research with mouse models has borne out the hypothesis that SCN − may be a useful intervention for resolving infection and inflammation [14-16]. Similarly, recent clinical data supports the hypothesis of a beneficial role for SCN − in human health [17,18].…”
Section: Introductionmentioning
confidence: 99%
“…Similarly, serum SCN - levels in smokers correlate with a higher deposition of oxidised LDL and fatty streak formation in the arteries [34] , [35] . However, supplementation of transgenic, atherosclerosis-prone, mice that over-express human MPO, with SCN - resulted in a decreased extent of lesion formation [36] . The reactivity of HOCl and HOSCN are strikingly different [37] , which results in the formation of modified LDL particles that have distinct cellular effects [27] , [38] , [39] .…”
Section: Introductionmentioning
confidence: 99%